Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238

Cancer

Volumn 92, Issue 5, 2001, Pages 1168-1176

  Plonowski, Artur ^a,b   Schally, Andrew V ^a   Koppan, Miklos ^a,b,c   Nagy, Attila ^a,b   Arencibia, Jose M ^a,b   Csernus, Balazs ^b   Halmos, Gabor ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Cytotoxic; Ovarian carcinoma; Somatostatin receptors; Targeted chemotherapy

Indexed keywords

CARBOXYLESTERASE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARBOXYLIC ESTER HYDROLASES; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; MICROSATELLITE REPEATS; OVARIAN NEOPLASMS; PYRROLES; RADIOLIGAND ASSAY; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035447401     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010901)92:5<1168::AID-CNCR1435>3.0.CO;2-6     Document Type: Article

References (39)

1. Cancer statistics, 1999
2. Chemotherapy of advanced ovarian cancer
3. Treatment of refractory and recurrent ovarian cancer
4. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I/II study
5. Chemotherapy targeted to hormone receptors on tumors
6. The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancers
7. 6]luteinizing hormone releasing hormone and epidermal growth factor n human ovarian cancer
8. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone
9. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice
10. 3]octreotide; the Rotterdam experience with more than 1000 patients
11. Yttrium-90-labeled somatostatin-analogue for cancer treatment
12. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues
13. Human ovarian cancers express somatostatin receptors
14. In vitro detection of somatostatin receptors in human tumors
15. Somatostatin receptors in differentiated ovarian tumors
16. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization
17. Evaluation of receptors for somatostatin in various tumors using different analogs
18. 1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector
19. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
20. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses
21. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238
22. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted analogue of somatostatin AN-238
23. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin
24. A targeted cytotoxic somatostatin analogue AN-238 inhibits growth of H-69 small cell lung carcinoma (SCLC) and H-157 Non-SCLC in nude mice
25. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238
26. Somatostatin receptor-based scintigraphy and antitumor treatment-an expanding vista
27. Characterization and development of UCI-107, a primary human ovarian carcinoma cell line
28. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin-14-O-hemiglutarate in mouse and human sera in vitro: Implications for the design of preclinical studies
29. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
30. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1,000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxorubicin
31. Targeting of cytotoxic bombesin analog AN-215 to H-69 small cell lung carcinoma as demonstrated by semiquantitative microsatellite analysis in vitro
32. In vitro targeting of cytotoxic analog of luteinizing hormone-releasing hormone (LHRH) AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses
33. The somatostatin analogue, octreotide, modifies both steroidogenesis and IGFBP-1 secretion in human luteinizing granulosa cells
34. Regulation of insulin-like growth factor-binding protein-1 and progesterone secretion from human granulosa-lutein cells: Effects of octreotide and insulin
35. Cloning, expression, pharmacology and tissue distribution of the mouse somatostatin receptor subtype 5
36. Interspecies differences in enzymes reacting with organophosphates and their inhibition by paraoxon in vitro
37. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215
38. 111In-pentreotide
39. Peptide analogs in the therapy of prostate cancer